Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Arrowhead Pharmaceuticals, Inc.'s quarterly P/E stands at 75.4x.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -5186.07 | 75.44 | — | — | 1.16 | — | — | — | — | — | — | — | 14.11 |
| — | — | — | — | — | — | — | — | — | — | — | — | -49.7% | |
| P/S Ratio | 10.48 | 8.84 | 4.56 | 19.78 | 0.79 | 234.71 | 25.04 | — | — | 231.41 | 44.78 | 60.28 | 4.69 |
| — | -96.2% | -81.8% | — | — | +1.4% | -44.1% | — | — | +1246.1% | +61.8% | +109.9% | -42.6% | |
| P/B Ratio | 16.81 | 16.60 | 9.30 | 4.23 | 2.50 | 41.86 | 12.37 | 9.52 | 7.12 | 18.92 | 10.04 | 9.99 | 5.91 |
| — | -60.3% | -24.8% | -55.6% | -64.8% | +121.2% | +23.2% | -4.7% | +20.5% | +74.4% | +20.2% | +27.2% | -46.2% | |
| P/FCF | 55.41 | 206.07 | 89.99 | — | 0.94 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 76.09 | 52.05 | 26.20 | — | 1.46 | — | — | — | — | — | — | — | 13.25 |
| — | — | — | — | — | — | — | — | — | — | — | — | -52.3% | |
| EV / EBIT | 94.60 | 48.39 | 22.88 | — | 1.45 | — | — | — | — | — | — | — | 12.77 |
| — | — | — | — | — | — | — | — | — | — | — | — | -53.8% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Arrowhead Pharmaceuticals, Inc.'s operating margin was 15.5% in Q1 2026, down 1.7 pp QoQ and up 6471.9 pp YoY. The trailing four-quarter average of -123.3% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.1% | 100.0% | 100.0% | 77.6% | 100.0% | 100.0% | 42.5% | — | — | 100.0% | 76.0% | — | — |
| — | 0.0% | +135.4% | — | — | 0.0% | -44.1% | — | — | — | — | — | — | |
| Operating Margin | 11.9% | 15.5% | 17.2% | -596.2% | 70.2% | -6456.5% | -687.6% | — | — | -3845.3% | -673.0% | -649.0% | 32.9% |
| — | +100.2% | +102.5% | — | — | -67.9% | -2.2% | — | — | -5608.1% | -153.5% | -188.5% | +20.3% | |
| Net Margin | -0.2% | 11.7% | -9.3% | -631.1% | 68.3% | -6923.4% | -722.9% | — | — | -3741.6% | -681.4% | -650.5% | 33.3% |
| — | +100.2% | +98.7% | — | — | -85.0% | -6.1% | — | — | -5563.0% | -151.6% | -192.7% | +13.9% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -0.5% | 5.8% | -4.6% | -29.1% | 100.1% | -140.1% | -64.3% | -40.9% | -37.5% | -57.7% | -32.8% | -24.3% | 11.3% |
| — | +104.1% | +92.8% | +28.9% | +367.2% | -142.9% | -96.3% | -68.4% | -431.4% | -468.3% | -71.1% | -56.3% | +5.0% | |
| ROA | -0.1% | 2.0% | -1.7% | -11.9% | 28.6% | -16.1% | -16.9% | -18.6% | -15.8% | -19.1% | -14.0% | -12.2% | 5.5% |
| — | +112.5% | +90.0% | +36.1% | +280.7% | +15.8% | -20.0% | -52.2% | -390.2% | -265.8% | -18.6% | -23.3% | -17.4% | |
| ROIC | 7.2% | 2.8% | 3.0% | -10.6% | 27.1% | -13.3% | -14.6% | -17.7% | -14.8% | -19.2% | -17.7% | -19.9% | 10.5% |
| — | +121.2% | +120.4% | +40.2% | +282.3% | +30.5% | +17.3% | +11.2% | -241.6% | -102.8% | -13.6% | -47.2% | +17.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Arrowhead Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 14.6x, down from 16.6x last quarter — elevated, raising questions about debt serviceability. The current ratio has weakened 44.5% YoY to 3.38x, tightening the short-term liquidity position.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.66 | 1.22 | 1.66 | 1.37 | 1.08 | 15.55 | 4.46 | 1.34 | 0.81 | 2.26 | 1.34 | 0.22 | 0.18 |
| — | -92.1% | -62.7% | +2.4% | +34.1% | +588.7% | +233.9% | +518.5% | +353.5% | +989.8% | +584.9% | +26.6% | +214.3% | |
| Debt / EBITDA | 6.85 | 14.57 | 16.59 | — | 1.91 | — | — | — | — | — | — | — | 1.63 |
| — | — | — | — | — | — | — | — | — | — | — | — | +180.7% | |
| Current Ratio | 4.86 | 3.38 | 4.86 | 4.87 | 5.15 | 6.09 | 6.74 | 4.65 | 8.31 | 3.73 | 3.98 | 6.69 | 6.60 |
| — | -44.5% | -27.9% | +4.6% | -38.1% | +63.0% | +69.5% | -30.5% | +26.0% | -9.2% | +46.8% | +98.5% | +119.3% | |
| Quick Ratio | 4.86 | 3.38 | 4.86 | 4.87 | 5.15 | 6.09 | 6.74 | 4.65 | 8.31 | 3.73 | 3.98 | 6.55 | 6.60 |
| — | -44.5% | -27.9% | +4.6% | -38.1% | +63.0% | +69.5% | -29.0% | +26.0% | -19.6% | +38.8% | +97.4% | +122.8% | |
| Interest Coverage | 1.10 | 1.81 | 2.03 | -6.79 | 17.62 | -7.46 | -11.07 | -34.58 | -17.42 | -25.44 | -20.59 | -19.91 | 9.52 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonArrowhead Pharmaceuticals, Inc.'s current P/E is -5186.1x. The average P/E over the last 2 quarters is 38.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Arrowhead Pharmaceuticals, Inc.'s current operating margin is 11.9%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Arrowhead Pharmaceuticals, Inc.'s business trajectory between earnings reports.